David Venet

3.3k total citations
48 papers, 1.6k citations indexed

About

David Venet is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, David Venet has authored 48 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 20 papers in Cancer Research and 18 papers in Molecular Biology. Recurrent topics in David Venet's work include Cancer Genomics and Diagnostics (13 papers), Gene expression and cancer classification (10 papers) and Cancer Immunotherapy and Biomarkers (8 papers). David Venet is often cited by papers focused on Cancer Genomics and Diagnostics (13 papers), Gene expression and cancer classification (10 papers) and Cancer Immunotherapy and Biomarkers (8 papers). David Venet collaborates with scholars based in Belgium, Italy and United States. David Venet's co-authors include Vincent Detours, Jacques E. Dumont, Christos Sotiriou, Françoise Rothé, Yacine Barèche, Michail Ignatiadis, Martine Piccart, Philippe Aftimos, Carine Maenhaut and Hugues Bersini and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

David Venet

46 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Venet Belgium 19 750 660 579 291 169 48 1.6k
Bradley M. Broom United States 24 1.0k 1.3× 592 0.9× 567 1.0× 474 1.6× 114 0.7× 63 1.9k
J. W. Chapman United States 11 450 0.6× 914 1.4× 473 0.8× 178 0.6× 179 1.1× 15 1.4k
Tatiana Vidaurre Peru 13 539 0.7× 583 0.9× 529 0.9× 184 0.6× 79 0.5× 56 1.2k
L Rhoda Molife United Kingdom 18 836 1.1× 872 1.3× 359 0.6× 419 1.4× 115 0.7× 44 1.6k
Hans Bojar Germany 24 744 1.0× 580 0.9× 557 1.0× 287 1.0× 184 1.1× 97 2.0k
Sherry X. Yang United States 21 1.8k 2.4× 1.5k 2.2× 904 1.6× 372 1.3× 203 1.2× 54 3.2k
Rosalie Nolley United States 23 814 1.1× 317 0.5× 400 0.7× 1.0k 3.5× 152 0.9× 55 2.0k
Andrea Bild United States 9 1.9k 2.6× 710 1.1× 791 1.4× 429 1.5× 110 0.7× 25 2.7k
Pradip De United States 22 1.0k 1.4× 988 1.5× 596 1.0× 438 1.5× 178 1.1× 36 2.0k
Ronglai Shen United States 17 1.3k 1.7× 841 1.3× 1.0k 1.8× 760 2.6× 141 0.8× 48 2.7k

Countries citing papers authored by David Venet

Since Specialization
Citations

This map shows the geographic impact of David Venet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Venet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Venet more than expected).

Fields of papers citing papers by David Venet

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Venet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Venet. The network helps show where David Venet may publish in the future.

Co-authorship network of co-authors of David Venet

This figure shows the co-authorship network connecting the top 25 collaborators of David Venet. A scholar is included among the top collaborators of David Venet based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Venet. David Venet is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Venet, David, Ghizlane Rouas, Xiaoxiao Wang, et al.. (2024). Spatial transcriptomic and proteomic insight into Trop-2, HER2, and AR expression: A pathway to tailored therapies in triple-negative breast cancer.. Journal of Clinical Oncology. 42(16_suppl). e12576–e12576. 2 indexed citations
2.
Rediti, Mattia, Danai Fimereli, Zéna Wimana, et al.. (2024). Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: An Analysis of the ZEPHIR Clinical Trial. Clinical Cancer Research. 31(1). 110–121. 3 indexed citations
3.
Rediti, Mattia, David Venet, Marion Maetens, et al.. (2024). Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial. Nature Communications. 15(1). 10402–10402. 3 indexed citations
4.
Buisseret, Laurence, Yacine Barèche, David Venet, et al.. (2024). The long and winding road to biomarkers for immunotherapy: a retrospective analysis of samples from patients with triple-negative breast cancer treated with pembrolizumab. ESMO Open. 9(5). 102964–102964. 4 indexed citations
5.
Rediti, Mattia, David Venet, Samira Majjaj, et al.. (2023). Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22–00. Clinical Cancer Research. 29(23). 4908–4919. 7 indexed citations
6.
Wang, Xiaoxiao, L. Collet, Mattia Rediti, et al.. (2023). Predictive Biomarkers for Response to Immunotherapy in Triple Negative Breast Cancer: Promises and Challenges. Journal of Clinical Medicine. 12(3). 953–953. 33 indexed citations
7.
Semba, Takashi, Mattia Rediti, Daniel J. McGrail, et al.. (2023). Abstract PD9-07: Role of immunosuppressive JNK pathway in the tumor microenvironment among Triple Negative Breast Cancer subtypes in IBCSG Trial 22-00. Cancer Research. 83(5_Supplement). PD9–7. 1 indexed citations
8.
Agostinetto, Elisa, Matteo Lambertini, Françoise Rothé, et al.. (2022). Circulating Tumor DNA After Neoadjuvant Chemotherapy in Breast Cancer Is Associated With Disease Relapse. JCO Precision Oncology. 6(6). e2200148–e2200148. 48 indexed citations
9.
Rothé, Françoise, David Venet, Dieter Peeters, et al.. (2022). Interrogating breast cancer heterogeneity using single and pooled circulating tumor cell analysis. npj Breast Cancer. 8(1). 79–79. 15 indexed citations
10.
Wang, Xiaoxiao, David Venet, Denis Larsimont, et al.. (2022). 1711P Spatial transcriptomics reveals substantial heterogeneity in TNBC tumor and stroma compartments with potential clinical implications. Annals of Oncology. 33. S1321–S1322. 1 indexed citations
11.
Gombos, Andrea, David Venet, Lieveke Ameye, et al.. (2021). FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer. npj Breast Cancer. 7(1). 125–125. 14 indexed citations
12.
Richard, François, Samira Majjaj, David Venet, et al.. (2020). Characterization of Stromal Tumor-infiltrating Lymphocytes and Genomic Alterations in Metastatic Lobular Breast Cancer. Clinical Cancer Research. 26(23). 6254–6265. 19 indexed citations
13.
Barèche, Yacine, David Venet, Michail Ignatiadis, et al.. (2018). Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis. Annals of Oncology. 29(4). 895–902. 254 indexed citations
14.
Sonnenblick, Amir, Sylvain Brohée, Debora Fumagalli, et al.. (2015). Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer. BMC Medicine. 13(1). 177–177. 44 indexed citations
15.
Timmermans, Catherine, David Venet, & Tomasz Burzykowski. (2015). Data-driven risk identification in phase III clinical trials using central statistical monitoring. International Journal of Clinical Oncology. 21(1). 38–45. 16 indexed citations
16.
Venet, David, Vincent Detours, & Hugues Bersini. (2012). A Measure of the Signal-to-Noise Ratio of Microarray Samples and Studies Using Gene Correlations. PLoS ONE. 7(12). e51013–e51013. 13 indexed citations
17.
Staveren, Wilma C.G. van, David Weiss Solís, David Venet, et al.. (2005). Gene expression in human thyrocytes and autonomous adenomas reveals suppression of negative feedbacks in tumorigenesis. Proceedings of the National Academy of Sciences. 103(2). 413–418. 49 indexed citations
18.
Mircescu, Hortensia, David Venet, Agnès Burniat, et al.. (2005). Gene expression in thyroid autonomous adenomas provides insight into their physiopathology. Oncogene. 24(46). 6902–6916. 22 indexed citations
19.
Detours, Vincent, David Venet, Bogdanova Ti, et al.. (2005). Absence of a specific radiation signature in post-Chernobyl thyroid cancers. British Journal of Cancer. 92(8). 1545–1552. 56 indexed citations
20.
Venet, David, et al.. (2001). Separation of samples into their constituents using gene expression data. Bioinformatics. 17(suppl_1). S279–S287. 94 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bradley M. Broom Breakdown of academic impact, for papers by J. W. Chapman Breakdown of academic impact, for papers by Tatiana Vidaurre Breakdown of academic impact, for papers by L Rhoda Molife Breakdown of academic impact, for papers by Hans Bojar Breakdown of academic impact, for papers by Sherry X. Yang Breakdown of academic impact, for papers by Rosalie Nolley Breakdown of academic impact, for papers by Andrea Bild Breakdown of academic impact, for papers by Pradip De Breakdown of academic impact, for papers by Ronglai Shen
Rankless by CCL
2026